Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neurologist ; 26(4): 149-152, 2021 Jul 06.
Artigo em Inglês | MEDLINE | ID: mdl-34190209

RESUMO

INTRODUCTION: Parkinsonism-hyperpyrexia syndrome (PHS) is a rare and potentially fatal complication of Parkinson disease (PD) characterized by a neuroleptic malignant-like syndrome due to abrupt discontinuation of antiparkinsonian medications. CASE REPORT: A 79-year-old woman with late-stage PD presented at the hospital with neuropsychiatric and uncontrolled parkinsonian motor symptoms. Soon after the abrupt discontinuation of amantadine, the patient suddenly presented with global rigidity, global unresponsiveness, diaphoresis, tachycardia, recurrent hyperpyrexia, and a mildly elevated creatine kinase, which lead to the diagnosis of PHS. Amantadine was then reinitiated and her symptoms resolved within 10 days. CONCLUSIONS: Amantadine is an antiparkinsonian medication scarcely associated with PHS. The few reported cases are further summarized and discussed in this article. This case highlights the importance of early recognition of PHS, which may be caused by changes in other antiparkinson agents such as amantadine, and the need to slowly titrate such agents.


Assuntos
Síndrome Maligna Neuroléptica , Doença de Parkinson , Transtornos Parkinsonianos , Idoso , Amantadina/efeitos adversos , Antiparkinsonianos/efeitos adversos , Feminino , Humanos , Síndrome Maligna Neuroléptica/etiologia , Doença de Parkinson/tratamento farmacológico , Transtornos Parkinsonianos/induzido quimicamente
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...